ストックスクリーナーアプリを入手
73.27
4.56%
-3.50
アフターアワーズ：
73.27
前日終値:
$76.77
開ける：
$75.4
24時間の取引高:
6.36M
Relative Volume:
5.08
時価総額：
$6.08B
収益：
$1.73B
当期純損益:
$682.64M
株価収益率:
9.4708
EPS:
7.7364
ネットキャッシュフロー:
$411.18M
1週間 パフォーマンス:
-0.56%
1か月 パフォーマンス:
+2.52%
6か月 パフォーマンス:
-2.85%
1年 パフォーマンス:
+41.26%
1日の値動き範囲:
$72.04
$76.95
1週間の範囲:
$71.80
$77.13
52週間の値動き範囲:
$43.17
$87.50
Ptc Therapeutics Inc Stock (PTCT) Company Profile
名前
Ptc Therapeutics Inc
セクター
電話
(908) 222-7000
住所
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
73.27 | 6.37B | 1.73B | 682.64M | 411.18M | 7.7364 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Raymond James | Outperform |
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2025-12-01 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-06-17 | 開始されました | Truist | Buy |
| 2025-05-09 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-05-07 | アップグレード | Citigroup | Sell → Neutral |
| 2025-03-11 | アップグレード | BofA Securities | Underperform → Neutral |
| 2025-03-07 | 開始されました | Scotiabank | Sector Perform |
| 2024-12-13 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-09-04 | 開始されました | Robert W. Baird | Outperform |
| 2024-08-26 | 再開されました | UBS | Buy |
| 2024-05-20 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-10-30 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-10-27 | ダウングレード | Citigroup | Neutral → Sell |
| 2023-10-06 | ダウングレード | Truist | Buy → Hold |
| 2023-09-18 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-09-15 | ダウングレード | Raymond James | Outperform → Underperform |
| 2023-03-17 | 開始されました | SVB Securities | Market Perform |
| 2022-12-14 | 開始されました | Goldman | Sell |
| 2022-09-12 | 開始されました | Jefferies | Buy |
| 2022-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-09-01 | 開始されました | Citigroup | Buy |
| 2022-04-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2021-10-18 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-04-26 | 再開されました | Credit Suisse | Neutral |
| 2021-03-29 | アップグレード | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-01-05 | アップグレード | Citigroup | Neutral → Buy |
| 2020-11-30 | ダウングレード | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-10-07 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-04-09 | アップグレード | Citigroup | Neutral → Buy |
| 2020-02-20 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-02-20 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-05-13 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | 開始されました | Bernstein | Outperform |
| 2018-10-03 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-07-19 | 開始されました | Credit Suisse | Outperform |
| 2018-06-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2018-01-29 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | アップグレード | JP Morgan | Underweight → Neutral |
| 2017-10-26 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | ダウングレード | JP Morgan | Neutral → Underweight |
すべてを表示
Ptc Therapeutics Inc (PTCT) 最新ニュース
[8-K] PTC THERAPEUTICS, INC. Reports Material Event - Stock Titan
PTC Therapeutics prices convertible notes for refinancing - MSN
PTC Therapeutics (PTCT) Launches $500M Convertible Notes Offerin - GuruFocus
PTC Therapeutics Prices $500 Million Notes Offering - marketscreener.com
Biotech PTC sells $500M 0% notes at 40% premium to stock - Stock Titan
PTC Therapeutics Prices $500 Million 0% Convertible Senior Notes Due 2031 - TradingView
PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes - TradingView
PTC Therapeutics Plans $500 Million Convertible Notes Offering to Refinance 2026 Notes - marketscreener.com
PTC Therapeutics plans $500M notes to refinance 2026 debt, buy stock - Stock Titan
PTC Therapeutics Q1 earnings call highlights - MSN
PTC Therapeutics Insider Sold Shares Worth $1,595,775, According to a Recent SEC Filing - Moomoo
PTC Therapeutics climbs after guidance hike - MSN
96,860 Shares in PTC Therapeutics, Inc. $PTCT Acquired by Castleark Management LLC - MarketBeat
Insider Sell: Eric Pauwels Sells 21,277 Shares of PTC Therapeuti - GuruFocus
PTC Therapeutics CBO Eric Pauwels sells $1.6 million in stock - Investing.com UK
PTC Therapeutics CBO Eric Pauwels sells $1.6 million in stock By Investing.com - Investing.com South Africa
PTC Therapeutics (PTCT) CBO sells shares under 10b5-1 trading plan - Stock Titan
Sector Gamma AS Sells 56,189 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC THERAPEUTICS INC (NASDAQ:PTCT) Scores Perfect 10/10 For Technical Breakout Setup - ChartMill
Fidelity affiliate seeks to sell PTCT (NASDAQ: PTCT) 17,566 shares on 06/10/2026 - Stock Titan
PTC Therapeutics upgraded at Jefferies on Sephience - MSN
Los Angeles Capital Management LLC Has $2.46 Million Stock Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Key facts: PTC Therapeutics director resigns; posts record revenue - TradingView
PTC Therapeutics Director Resigns, Moves to Advisory Role - TipRanks
Alethia Young resigns from PTC Board, to serve as consultant - TradingView
PTC Therapeutics (NASDAQ: PTCT) director Alethia Young shifts to consultant role - Stock Titan
PTC Therapeutics Shares Rise After Upgrade From Citigroup - Moomoo
Transcript : PTC Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 09 - marketscreener.com
PTCT Raised by Citigroup -- Price Target Increased to $108 - GuruFocus
PTC Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Citigroup Upgrades PTC Therapeutics to Buy From Hold, Raise Price Target to $108 From $76 - marketscreener.com
PTC Therapeutics (PTCT) reports Q1 loss, tops revenue estimates - MSN
19,877 Shares in PTC Therapeutics, Inc. $PTCT Purchased by Commonwealth of Pennsylvania Public School Empls Retrmt SYS - MarketBeat
A Look At PTC Therapeutics (PTCT) Valuation As Models Flag A Potential Discount - Sahm
Why The PTC Therapeutics (PTCT) Story Is Shifting As Sephience Assumptions Drive New Valuations - Yahoo Finance
Total operating expenses of PTC Therapeutics, Inc. – XETR:BH3 - TradingView
BI Asset Management Fondsmaeglerselskab A S Purchases 64,472 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Gross profit of PTC Therapeutics, Inc. – XETR:BH3 - TradingView
PTC Therapeutics Shareholders Back Board, Pay and Auditor - The Globe and Mail
Total debt per share of PTC Therapeutics, Inc. – XETR:BH3 - TradingView
PTC Therapeutics, Inc. Cash Flow – XETR:BH3 - TradingView
ETFs Investing in PTC Therapeutics, Inc. Stocks - TradingView
PTC Therapeutics, Inc. 8-K Filing June 2026 – Company Information, Stock Details, and SEC Compliance - Minichart
Precision Trading with Ptc Therapeutics Inc. (PTCT) Risk Zones - Stock Traders Daily
PTC Therapeutics (NASDAQ: PTCT) investors approve directors, auditor and pay at 2026 meeting - Stock Titan
Geode Capital Management LLC Boosts Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
Gastroparesis Market Shows Strong Future Potential with Increasing Industry Investments by 2036 – DelveInsight | Vanda Pharma, Dr. Falk Pharma GmbH, Alfasigma S.p.A., PTC Therapeutics, CinDome Pharma - Barchart.com
Gastroparesis Market Shows Strong Future Potential with - openPR.com
PTC Therapeutics Drops 6.3% Amid Sector-Wide Selling - AlphaStreet
PTC Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Ptc Therapeutics Inc (PTCT) 財務データ
収益
当期純利益
現金流量
EPS
Ptc Therapeutics Inc (PTCT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Pauwels Eric | CHIEF BUSINESS OFFICER |
Jun 10 '26 |
Sale |
75.00 |
21,277 |
1,595,775 |
73,411 |
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):